NeuExcell Signs a Research Agreement with Spark to Develop a Novel Gene Therapy for Huntington's Disease
Shots:
- NeuExcell is eligible to receive $190M up front- license fees- R&D- and sales milestones along with royalties
- Spark gets the option to license the global exclusive rights of NeuExcell's HD program & will receive access to NeuExcell's neuro-regenerative gene therapy platform & capabilities. NeuExcell is developing AAVs based neuroregenerative gene therapy to regenerate functional new neurons at the site of the neurodegeneration
- The focus of the collaboration is to develop a safe and effective treatment for patients with HD by using NeuExcell's neuroregenerative gene therapy platform
| Ref: PR Newswire | Image: PR Newswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com